Von Hippel-Lindau Disease: Clinical Features and Management

Genetic Basis and Inheritance

Von Hippel-Lindau disease is an autosomal dominant hereditary cancer syndrome caused by pathogenic variants in the VHL tumor suppressor gene, with lifetime penetrance approaching 100% by age 75, according to the National Cancer Institute 1
Approximately 80% of individuals have an affected parent, while 20% arise from de novo mutations, as reported by the American College of Medical Genetics 2
The incidence is estimated at 1 in 36,000 live births, as stated by the Clinical Cancer Research journal 1

CNS hemangioblastomas occur in 60-80% of patients, with youngest reported diagnosis at age 9 years, causing significant morbidity through mass effect, as noted by the National Institute of Neurological Disorders and Stroke 1
Retinal hemangioblastomas develop in 38% of patients, with cumulative probability reaching nearly 80% in those older than 80 years, leading to vision loss in approximately 20% of patients, as reported by the American Academy of Ophthalmology 3, 4
Multiple renal cysts are common, and clear cell renal cell carcinoma develops in up to 70% of patients, representing a leading cause of mortality, as stated by the American Urological Association 1
Pheochromocytomas occur in 7-20% of families, associated with specific missense mutations, as noted by the Endocrine Society 1

A clinical diagnosis can be established in two scenarios: with family history, or without family history, using specific criteria, as outlined by the National Comprehensive Cancer Network 1, 3
Comprehensive surveillance paradigms have substantially mitigated risks, leading to early tumor recognition and multidisciplinary management, as reported by the American College of Surgeons 1, 2
Early recognition and testing of at-risk individuals is key to preventing morbidity and mortality, as stated by the American Academy of Pediatrics 1, 2

Retinal hemangioblastomas can develop as early as the first year of life, necessitating screening within 12 months after birth 5, 6, 7
The youngest documented case of retinal hemangioblastoma in natural history studies was a 2-year-old child 5, 8, 9
Mean age at diagnosis of retinal hemangioblastomas ranges from 17 to 29 years across multiple cohorts 8, 9
Natural history studies demonstrate that 95% of patients are identified by 37 years of age 9

Ocular screening must begin within 12 months after birth and continue throughout life 5, 6, 7, 8, 9, 10
Examinations should occur every 6-12 months until age 30, then at least yearly thereafter 5, 6, 7, 8, 9, 10
Sporadic presentations (without family history) become more likely with increasing age at presentation 5, 6

Do not delay genetic testing or surveillance based on young age alone, as cases have been documented in very young children 5, 8, 9
Do not assume older age at presentation indicates sporadic disease, as VHL manifestations can first appear in middle or late adulthood despite genetic predisposition being present from birth 5, 6
Even a solitary retinal hemangioblastoma at any age warrants genetic testing and comprehensive evaluation 5, 6, 7, 10

Historical data showed median life expectancy of only 49 years 10
Recent improvements in surveillance and treatment have extended mean life expectancy to 60-67 years for individuals born in 2000 6, 10